Fingerprint
Dive into the research topics where Bryan K Kee is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial
Folkert, I. W., Mehran, R., Sun, R., Morris, V. K., Overman, M. J., Kee, B., Antonoff, M. B., Tzeng, C. W., Dasari, A., Tran Cao, H., Parseghian, C. M., Vilar, E., Willis, J., Newhook, T. E., Hofstetter, W., Kopetz, S. E., Vauthey, J. N. & Chun, Y. S., Apr 2026, In: Annals of surgical oncology. 33, 4, p. 2899-2907 9 p.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Scopus citations -
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
Pattalachinti, V. K., Haque, E., Yousef, M., Yousef, A., Chowdhury, S., Overman, M., Parseghian, C. M., Morris, V. K., Kee, B., Huey, R. W., Raghav, K., Court, C. M. & Shen, J. P., Dec 2025, In: npj Precision Oncology. 9, 1, 38.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
Morris, V. K., Parseghian, C. M., Bahrambeigi, V., Abdelfattah, N., Xiao, L., Agrawal, A., Lin, K., Raghav, K. P. S., Wolff, R. A., Dasari, A., Huey, R. W., Kee, B. K., Overman, M. J., Willis, J. A., Le, P. H., Escano, M., Baig, Y. C., Pan, K., Menter, D. & Tam, A. L. & 13 others, , Nov 10 2025, In: Cancer cell. 43, 11, p. 2106-2118.e3Research output: Contribution to journal › Article › peer-review
Open Access14 Link opens in a new tab Scopus citations -
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
Pellatt, A. J., Bent, A., Hornstein, N., Parseghian, C., Huey, R., Raghav, K., Morris, V., Overman, M., Morelli, P., Willis, J., Le, P., Shen, J. P., Kee, B., Eluri, M., Higbie, V., Alfaro-Munoz, K., Aziz, K., Kell, R., Sun, R. & Kopetz, S. & 1 others, , Jul 1 2025, In: JCO Precision Oncology. 9, e2500142.Research output: Contribution to journal › Article › peer-review
2 Link opens in a new tab Scopus citations -
The Landscape of ctDNA in Appendiceal Adenocarcinoma
White, M. G., Zeineddine, M. A., Fallon, E. A., Zeineddine, F. A., Dansby, J., Chowdhury, S., Hornstein, N., Yousef, A., Yousef, M., Bhutiani, N., Gu, Y., Kee, B., Dasari, A., Overman, M. J., Raghav, K., Kopetz, S., Uppal, A., Taggart, M., Newhook, T. & Fournier, K. & 3 others, , Feb 1 2025, In: Clinical Cancer Research. 31, 3, p. 551-560 10 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Link opens in a new tab Scopus citations